Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
497.61%
operating margin TTM
508.23%
revenue TTM
143.41 Thousand
revenue per share TTM
0.11$
valuation ratios | |
|---|---|
| pe ratio | -1.37 |
| peg ratio | 0.02 |
| price to book ratio | 1.44 |
| price to sales ratio | -6.81 |
| enterprise value multiple | -1.74 |
| price fair value | 1.44 |
profitability ratios | |
|---|---|
| gross profit margin | 4.25% |
| operating profit margin | 508.23% |
| pretax profit margin | 497.61% |
| net profit margin | 497.61% |
| return on assets | -87.5% |
| return on equity | -80.0% |
| return on capital employed | -106.48% |
liquidity ratios | |
|---|---|
| current ratio | 5.81 |
| quick ratio | 5.81 |
| cash ratio | 2.38 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | -24.05 |
| cash conversion cycle | 24.05 |
| receivables turnover | 0.00 |
| payables turnover | -15.18 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.07 |
| debt equity ratio | 0.09 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.08 |
| interest coverage | -535.96 |
| cash flow to debt ratio | -11.07 |
cash flow ratios | |
|---|---|
| free cash flow per share | -17.76 |
| cash per share | 19.85 |
| operating cash flow per share | -17.74 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -11.07 |
| short term coverage ratios | -11.94 |
| capital expenditure coverage ratio | -1,398.81 |
Frequently Asked Questions
When was the last time Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) reported earnings?
Sensei Biotherapeutics, Inc. (SNSE) published its most recent earnings results on 14-11-2025.
What is Sensei Biotherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Sensei Biotherapeutics, Inc. (NASDAQ:SNSE)'s trailing twelve months ROE is -80.0%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Sensei Biotherapeutics, Inc. (SNSE) currently has a ROA of -87.5%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did SNSE's net profit margin stand at?
SNSE reported a profit margin of 497.61% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is SNSE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 5.81 in the most recent quarter. The quick ratio stood at 5.81, with a Debt/Eq ratio of 0.09.